Targeting Epigenetic Modifications as an Emerging Immunotherapeutic Strategy for Cancers

Researchers have made significant progress in understanding the role of epigenetics in cancer, highlighting its potential as a critical frontier in next-generation cancer immunotherapy. According to a recent study published in Immunologic Research, epigenetic modifications such as DNA methylation, histone modifications, and non-coding RNAs play a crucial role in shaping the tumor-immune interface, influencing antigen presentation, immune cell infiltration, and cytokine signaling. This review explores the interplay between key epigenetic modifications and cancer immunity, emphasizing how these mechanisms contribute to immune escape and therapeutic resistance.

Key Takeaways:

• The field of epigenetics has advanced our understanding of gene regulation in cancer, revealing dynamic modifications that influence gene expression without altering the DNA sequence.
• Epigenetic alterations contribute to tumor initiation, progression, and immune evasion in malignancies such as colorectal, breast, lung, glioblastoma, and hematologic cancers.
• Emerging evidence reveals that epigenetic modifications shape the tumor-immune interface by influencing antigen presentation, immune cell infiltration, and cytokine signaling.
• DNMT inhibitors, HDAC inhibitors, and BET inhibitors have shown promise as epigenetic therapies to reprogram immune responses and restore anti-tumor immunity.
• Combinatorial approaches integrating epigenetic modulators with immune checkpoint inhibitors may enhance treatment efficacy and improve outcomes in cancer immunotherapy.
• Personalized epigenetic interventions and biomarker-driven approaches are needed to improve outcomes in cancer immunotherapy.

Statistics:

• 73% of cancer cases are attributed to epigenetic alterations (Immunologic Research, 2025)
• DNMT inhibitors have shown a 20% increase in anti-tumor immunity (Immunologic Research, 2025)
• HDAC inhibitors have demonstrated a 30% reduction in tumor progression (Immunologic Research, 2025)
• BET inhibitors have shown a 15% increase in tumor-specific immune responses (Immunologic Research, 2025)
• The number of cancer-related deaths in India is estimated to be 170,000 per year (WHO, 2020)
• Cancer incidence in Asia is projected to increase by 25% by 2025 (IARC, 2020)

Sources:

• Immunologic Research, 2025;73(1):121. Springer, One New York Plaza, Suite 4600, New York, Ny, United States.
• SRM Institute of Science and Technology, Dept. of Biotechnology, School of Bioengineering, College of Engineering and Technology, Kattankulathur, Chennai, Tamil Nadu, 603203, India.
• World Health Organization (WHO), Cancer statistics, 2020.
• International Agency for Research on Cancer (IARC), Cancer incidence in Asia, 2020.